Show Notes
Why is collaboration between regulators and the scientific community so essential to spur innovation in Alzheimer’s? In this episode, current and former regulatory officials take a page from the COVID-19 playbook, highlighting the vital need for transparent communication and cooperation across all stakeholders. The key: work together to advance incremental innovations that can eventually transform a devastating disease into a manageable condition.
More from The Growing Pandemic: How Innovation and Collaboration Can End Alzheimer’s
In this episode, experts will share their perspectives on the strengths and shortcomings of traditional approaches to value, potential evolutions or alternatives for the specific challenges of Alzheimer’s, and how to drive forward progress.
In this episode, experts will explore how blood-based biomarker tests can enable early, accurate Alzheimer’s diagnosis – and what’s needed to develop, standardize, and scale these tests.
This episode will explore how the lessons of vaccine development and distribution can be applied to Alzheimer’s disease. Experts will share their perspectives on the research, financing, regulatory, and healthcare system actions needed to develop and distribute new Alzheimer’s innovations globally.
What are the novel therapeutic approaches to Alzheimer’s disease and the current hurdles in research and innovation? In this episode, experts will discuss the current state of the field and the most promising approaches to accelerate drug discovery for Alzheimer’s and dementia.
How can technology empower skilled professionals to provide high quality care for individuals impacted by Alzheimer’s disease? In this episode, Chief Executive Officers of Home Instead and Honor Technology, Inc. discuss how high-touch, high-tech approaches to care can elevate and scale professional home care for Alzheimer’s disease and related dementias.